SHH4 Antibody

What is SHH4 Antibody and what role does it play in developmental biology research?

SHH4 Antibody (clone 5H4) is a monoclonal antibody that specifically targets the Sonic Hedgehog protein, which is essential for various patterning events during development. The intercellular signaling triggered by SHH is critical for the development of the notochord, neural tube and plate, as well as the polarizing of the anterior-posterior axis of developing limb buds . This antibody serves as a valuable tool for investigating these developmental processes by enabling the detection and visualization of SHH in various experimental contexts.

The antibody is of the IgG1 isotype and has demonstrated reactivity across multiple species including mouse, human, and monkey samples . Its specificity for unmodified SHH protein makes it particularly useful for tracking native SHH during developmental studies where post-translational modifications may alter protein function and localization.

What experimental techniques are compatible with SHH4 Antibody?

SHH4 Antibody has been validated for multiple experimental applications, providing researchers with versatile options for investigating SHH expression and function:

The antibody has been extensively tested in Western blotting applications across a diverse range of cell lines, demonstrating consistent detection of SHH protein . Researchers should perform validation in their specific experimental systems to determine optimal working dilutions.

How should researchers store and handle SHH4 Antibody to maintain its activity?

Proper storage and handling of SHH4 Antibody are essential for maintaining its activity and specificity. The antibody is typically shipped on wet ice , and researchers should adhere to the following guidelines:

• Store the antibody at -20°C for long-term storage or at 4°C for short-term use

• Avoid repeated freeze-thaw cycles by aliquoting the antibody into single-use volumes before freezing

• Protect from prolonged exposure to light, particularly for fluorophore-conjugated versions

• When preparing working dilutions, use high-quality, sterile buffers with appropriate pH (typically PBS with 0.1% BSA)

• Document lot numbers and maintain records of antibody performance to track any potential lot-to-lot variations

Maintaining proper temperature control throughout shipping, storage, and experimental procedures is critical for preserving antibody function and ensuring reproducible results.

How can SHH4 Antibody be utilized in cancer research models?

The Sonic Hedgehog signaling pathway has been implicated in the development and progression of various human cancers . SHH4 Antibody can be employed in multiple experimental approaches to investigate the role of SHH in cancer:

Therapeutic potential studies have demonstrated that C-terminal anti-Shh antibodies can reduce cell viability in cancer cell lines and inhibit tumor growth in xenograft models. For example, the C-terminal anti-Shh antibody Ab 1C11-2G4 significantly reduced tumor volume in A549 lung cancer xenografts when administered at 8 mg/kg intratumorally, three times weekly for three weeks .

Researchers can use SHH4 Antibody to:

• Detect and quantify SHH expression in tumor samples via immunohistochemistry

• Monitor changes in SHH expression during cancer progression using Western blot analysis

• Identify SHH-positive cell populations within heterogeneous tumor samples using flow cytometry

• Investigate the effects of SHH pathway inhibition on cancer cell proliferation, migration, and invasion

• Explore combination therapies targeting both SHH and other oncogenic pathways

Ex vivo analyses of xenograft tumors treated with anti-SHH antibodies have revealed reductions in SHH signal transduction and increased apoptosis, suggesting multiple mechanisms of anti-tumor activity .

What methodological considerations are important when using SHH4 Antibody in flow cytometry?

When utilizing SHH4 Antibody for flow cytometric analysis, researchers should consider several critical methodological aspects:

• Perform titration experiments to determine the optimal antibody concentration that maximizes signal-to-noise ratio

• Include appropriate isotype controls (IgG1) to assess non-specific binding

• Establish proper gating strategies based on unstained and single-stained controls

• Consider fixation and permeabilization protocols when detecting intracellular SHH protein

• Be aware that only a small percentage of cells may be SHH-positive (studies have shown as low as 0.11% in certain populations)

For cell surface SHH detection, avoid membrane permeabilization protocols. Comparative analyses have shown that clone 5H4 may recognize a higher number of SHH+ cells from mixed populations compared to other commercially available antibodies .

How can researchers validate the specificity of SHH4 Antibody in their experimental systems?

Validating antibody specificity is crucial for generating reliable and reproducible data. For SHH4 Antibody, researchers should implement multiple validation strategies:

• Positive and negative control samples: Use cell lines with known SHH expression levels (e.g., LNCaP, HepG2, PANC-1, HeLa positive; SHH-knockout cell lines as negative controls)

• Comparative analysis with other anti-SHH antibodies: Compare staining patterns with other validated antibodies targeting different epitopes of SHH

• Knockdown/knockout validation:

  • Perform siRNA-mediated knockdown of SHH

  • Generate CRISPR-Cas9 knockout models

  • Verify reduced antibody signal correlates with reduced SHH expression

• Peptide competition assays: Pre-incubate the antibody with purified SHH peptide before staining to confirm signal blockade

• Dual-labeling approaches: Co-stain with antibodies against known SHH interaction partners or downstream effectors

The hierarchical clustering approach described for antibody validation can be adapted to compare SHH4 Antibody reactivity patterns against various cell types and tissues, providing additional confidence in specificity .

What are common technical challenges when working with SHH4 Antibody and how can they be addressed?

Researchers may encounter several technical challenges when working with SHH4 Antibody:

For Western blotting applications specifically, SHH4 Antibody has been validated to detect SHH in multiple cell lines (LNCaP, HepG2, PANC-1, HeLa, SK-N-SH, F9, NIH3T3, COS7) . When troubleshooting, consider that SHH undergoes post-translational processing, resulting in multiple bands that may represent different forms of the protein.

How does SHH4 Antibody performance compare in detecting different forms of SHH protein?

Sonic Hedgehog protein undergoes complex processing, including auto-proteolytic cleavage and lipid modifications, resulting in multiple forms with distinct functional properties. Researchers should understand how SHH4 Antibody performs in detecting these various forms:

The SHH4 Antibody (clone 5H4) targets unmodified SHH protein . This specificity has important implications for experimental design:

• Full-length vs. processed SHH: The antibody may have differential affinity for the full-length precursor versus the processed N-terminal and C-terminal fragments

• Lipid modifications: Post-translational lipid modifications (palmitoylation, cholesterol addition) may affect epitope accessibility

• Species-specific considerations: While the antibody shows reactivity across multiple species (mouse, human, monkey) , sequence variations may affect binding efficiency

When analyzing Western blot results, researchers should anticipate potentially detecting multiple bands corresponding to different SHH forms. Careful interpretation is required, particularly when comparing results across different experimental systems or tissue types.

What approaches can researchers use to produce recombinant versions of SHH4 Antibody?

For researchers requiring large quantities of SHH4 Antibody or seeking to develop modified versions, recombinant production offers several advantages:

The protocol for generating recombinant antibodies from primary sequences involves:

• Generating antibody heavy and light chain plasmids: This requires knowledge of the primary sequence of the SHH4 antibody variable regions

• Transfection into HEK293 suspension culture cells: This expression system can produce high-yield recombinant monoclonal antibodies at relatively low cost compared to commercial sources

• Purification of the expressed antibody: Utilizing affinity chromatography techniques to isolate the antibody from culture supernatants

This approach allows researchers to:

• Produce large quantities of antibody with consistent quality

• Introduce modifications such as different Fc regions, fluorophore conjugations, or affinity tags

• Ensure reproducibility by avoiding lot-to-lot variations common with commercial antibodies

• Address ethical concerns associated with animal-derived antibodies

The recombinant production method has been validated to produce high-yield antibodies suitable for research applications, offering a cost-effective alternative to commercial sources .

What experimental controls should be included when using SHH4 Antibody for investigating SHH signaling in cancer models?

When designing experiments to investigate SHH signaling in cancer models using SHH4 Antibody, researchers should implement comprehensive controls:

• Positive and negative tissue/cell controls:

  • Positive controls: Tissues/cells with known SHH expression (e.g., developing neural tube, certain cancer cell lines)

  • Negative controls: SHH-knockout models or tissues with confirmed absence of SHH expression

• Antibody controls:

  • Isotype control (IgG1) to assess non-specific binding

  • Secondary antibody-only control to evaluate background signal

• Functional validation controls:

  • Parallel analysis of downstream SHH pathway components (GLI1/2 expression)

  • Comparison with established SHH pathway inhibitors (e.g., vismodegib)

• Treatment validation:

  • Dose-response experiments to establish optimal antibody concentrations

  • Time-course studies to determine temporal dynamics of SHH inhibition

  • Combination treatment controls when assessing synergistic effects with other therapies

Research using anti-SHH antibodies in cancer models has demonstrated that monitoring both SHH expression and downstream effectors (e.g., GLI transcription factors) is essential for comprehensive pathway analysis. Ex vivo analyses from xenograft studies revealed significant reductions in GLI transcripts and protein expression following anti-SHH antibody treatment, confirming functional target engagement .

How can computational approaches enhance SHH4 Antibody design and application?

Computational methods represent powerful tools for enhancing antibody design and application in SHH research:

Molecular dynamics simulations, similar to those employed in HIV antibody research, can identify key antibody mutations that prevent target escape and optimize binding affinity . For SHH4 Antibody research, computational approaches offer several advantages:

• Epitope mapping: Computational analysis can predict epitope-paratope interactions with atomic-level precision, enabling rational design of improved antibody variants

• Affinity maturation: In silico approaches can guide the introduction of specific mutations to enhance binding affinity and specificity

• Cross-reactivity prediction: Computational methods can assess potential cross-reactivity with related proteins, improving antibody specificity

• Developability assessment: Algorithms can predict physical properties important for antibody stability and manufacturing

Hierarchical clustering algorithms have been successfully applied to compare antibody reactivity patterns across different cell types . Similar approaches could be employed to:

• Compare SHH4 Antibody with other anti-SHH antibodies

• Identify optimal cell models for specific research questions

• Characterize epitope specificity across tissue types

What are the emerging applications of SHH4 Antibody in developmental biology and regenerative medicine?

The critical role of SHH signaling in development suggests several emerging applications for SHH4 Antibody in developmental biology and regenerative medicine:

• Stem cell differentiation protocols: SHH4 Antibody can be used to monitor and potentially modulate SHH signaling during directed differentiation of pluripotent stem cells

• Organoid development: Tracking SHH expression patterns in 3D organoid models can provide insights into morphogenesis and cellular organization

• Tissue engineering applications: Monitoring SHH signaling during engineered tissue development may improve biomimetic properties

• Developmental disorder models: SHH4 Antibody can facilitate investigation of SHH pathway dysregulation in congenital disorders

• Regenerative processes: Studying SHH expression during tissue regeneration may identify therapeutic targets for enhancing repair

The antibody has been specifically noted as suitable for stem cell research applications, particularly in pluripotent and early differentiation contexts . This suggests its utility in investigating the role of SHH in establishing cell identity and tissue patterning.